The restructuring events database contains factsheets with data on large-scale restructuring events reported in the principal national media and company websites in each EU Member State. This database was created in 2002.
Manufacturing (20 - 21) Manufacture of chemicals and pharmaceuticals 21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations 21.10 - Manufacture of basic pharmaceutical products
400 jobs Number of planned job losses
Announcement Date
11 January 2023
Employment effect (start)
1 September 2023
Foreseen end date
1 April 2024
Description
As part of its global reorganisation plan to reduce its workforce by 7%, or 8,000 jobs worldwide, the pharmaceutical group Novartis has announced it will cut around 400 jobs in France from its current 2,900 total. The global reorganisation consists of Novartis' merging its historical Pharmaceutical and Oncology divisions into a single Innovative Medicines division. The two production sites located in Huningue (Alsace) and Les Ulis (Essonne) will not be affected. The workforce reductions are concentrated at the headquarters in Rueil-Malmaison (Haut-de-Seine), which has 1,400 employees, due to the merger of the two divisions. If the 400 job cuts are confirmed after the consultation phase with staff representatives, the reduction in the workforce will be 14% for France, which is double the worldwide average for the reorganisation plan.
A previous reorganisation was recorded in the ERM Database in 2008 with 100 job losses (FR-Novartis-2008).
Eurofound (2023), Novartis, Internal restructuring in France, factsheet number 108183, European Restructuring Monitor. Dublin, https://apps.eurofound.europa.eu/restructuring-events/detail/108183.